Intuitive Surgical, Inc. (ISRG) Aandelenanalyse

Bedrijfsoverzicht

Intuitive Surgical, Inc. is a leading provider within the healthcare sector that specializes in medical instruments and supplies, specifically focusing on minimally invasive surgical technologies. The company develops, manufactures, and markets the da Vinci Surgical System, which enables physicians and healthcare providers globally to enhance the quality and accessibility of surgical care. Operating with a substantial scale, Intuitive Surgical boasts a market capitalization of $160.05 billion and generates annual revenue of $10.06 billion based on trailing twelve-month figures. With an employee base of 17,021 individuals, the company's financial magnitude, evidenced by a market cap exceeding $160 billion, places it among the most capitalized entities in the medical device industry, while its revenue stream of over $10 billion underscores its dominant market position and significant operational footprint.

Financiële gezondheid

Intuitive Surgical reported a trailing twelve-month revenue of $10.06 billion, resulting in a net income of $2.86 billion and an EBITDA of $3.56 billion. The gap between the $10.06 billion revenue and the $2.86 billion net income reveals a cost structure where operating expenses, including cost of goods sold, depreciation, and administrative costs, consume approximately 71.6% of gross revenue. The company generated free cash flow of $2.27 billion, which indicates a robust capacity to fund capital expenditures, repay debt, and potentially pursue strategic acquisitions without relying on external financing. The company maintains a highly conservative balance sheet with $5.93 billion in cash reserves against a relatively minor debt obligation of $170.90 million, further supported by a debt-to-equity ratio of 0.95. This liquidity position is reinforced by a current ratio of 4.88, which signifies that the company possesses nearly five times the current assets required to cover its short-term liabilities, ensuring strong short-term solvency. Profitability is further evidenced by a return on equity of 16.7% and a return on assets of 9.4%, metrics that demonstrate management's effectiveness in utilizing shareholder capital and total assets to generate substantial returns.

Waarderingsbeoordeling

The valuation of Intuitive Surgical is reflected in a trailing twelve-month P/E ratio of 57.11 and a forward P/E of 39.43. The significant difference between the trailing and forward P/E ratios implies that the market expects earnings growth in the future, as the forward multiple is substantially lower than the current historical multiple. The price-to-book ratio stands at 8.98, indicating that the company trades at a substantial premium over its book value, which is typical for firms with high intangible assets and strong competitive moats in the medical technology sector. Alternative valuation metrics such as the price-to-sales ratio of 15.90 and an EV/EBITDA of 43.39 suggest that the market values the company's revenue generation and earnings power at a high multiple relative to its peers. Regarding trading range, the stock reached a 52-week high of $603.88 and a 52-week low of $427.84; without a specific current share price provided in the available facts, the relative positioning to this range cannot be mathematically calculated from the data supplied. The stock exhibits a beta of 1.68, which means the share price is expected to be more volatile than the broader market, moving approximately 68% more than the market index during periods of fluctuation.

Growth & Income

Intuitive Surgical demonstrated revenue growth of 18.8% year-over-year alongside earnings growth of 16.6% year-over-year. The fact that earnings growth of 16.6% is slightly slower than revenue growth of 18.8% implies that the company's profit margins may be facing pressure from rising costs or pricing dynamics, though it remains a positive indicator of top-line expansion. The company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, meaning that instead of distributing cash to shareholders, the firm reinvests its earnings into research, development, and global market expansion. Consequently, the overall growth and income profile of Intuitive Surgical is characterized by aggressive reinvestment strategies rather than income generation through dividends, driving value creation through future profitability rather than current cash distributions.